[HTML][HTML] Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
BL Scott, MC Pasquini, BR Logan, J Wu… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
BL Scott, MC Pasquini, BR Logan, J Wu, SM Devine, DL Porter, RT Maziarz, ED Warlick…
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.govPurpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation
(HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with
reduced-intensity conditioning (RIC) would result in improved overall survival (OS)
compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a
phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia
or myelodysplastic syndromes.
(HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with
reduced-intensity conditioning (RIC) would result in improved overall survival (OS)
compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a
phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia
or myelodysplastic syndromes.
Abstract
Purpose
The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia or myelodysplastic syndromes.
ncbi.nlm.nih.gov